Xospata (gilteritinib) - Astellas
Vanflyta (quizartinib) - Daiichi Sankyo
Nexavar (sorafenib) - Bayer, Amgen
Rydapt (midostaurin) - Novartis
crenolanib besylate (ARO-002) - AROG
https://ash.confex.com/ash/2020/webprogram/Paper141169.html
 
Ahmad S. Alotaibi, MD1; Musa Yilmaz, MD2; Rashmi Kanagal-Shamanna, MD3; Sanam Loghavi, MD4; Tapan M. Kadia, MD2; Courtney D. DiNardo, MD, MSc2; Gautam Borthakur, MD2; Sherry A. Pierce, BSN, BA2; Sa A Wang, MD3; Guilin Tang, MD3; Veronica A Guerra, MD2; Bachar Samra, MD2; Naveen Pemmaraju, MD2; Elias Jabbour, MD2; Nicholas J. Short, MD2; Ghayas C. Issa, MD2; Maro Ohanian, DO2; Guillermo Garcia-Manero, MD2; Kapil N. Bhalla, MD5; Keyur P. Patel, MBBS, PhD3; Koichi Takahashi, MD, PhD2; Michael Andreeff, MD, PhD6; Jorge E. Cortes, MD7; Marina Konopleva, MD, PhD8; Farhad Ravandi, MBBS2; Hagop M. Kantarjian, MD2; Naval Daver, MD2
 
Nov 5, 2020
 
Prev Next